[go: up one dir, main page]

LT3658192T - Gliukokortikoidų receptorių agonistas ir jo imunokonjugatai - Google Patents

Gliukokortikoidų receptorių agonistas ir jo imunokonjugatai

Info

Publication number
LT3658192T
LT3658192T LTEP18833113.6T LT18833113T LT3658192T LT 3658192 T LT3658192 T LT 3658192T LT 18833113 T LT18833113 T LT 18833113T LT 3658192 T LT3658192 T LT 3658192T
Authority
LT
Lithuania
Prior art keywords
glucocorticide
immunoconjugates
receptor agonist
agonist
receptor
Prior art date
Application number
LTEP18833113.6T
Other languages
English (en)
Inventor
Adrian D. Hobson
Michael J. Mcpherson
Wendy Waegell
Christian GOESS
Axel Hernandez
Lu Wang
Christopher C. MARVIN
Ling C. Santora
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of LT3658192T publication Critical patent/LT3658192T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
LTEP18833113.6T 2017-12-01 2018-11-29 Gliukokortikoidų receptorių agonistas ir jo imunokonjugatai LT3658192T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593776P 2017-12-01 2017-12-01
US201762595054P 2017-12-05 2017-12-05
PCT/IB2018/059482 WO2019106609A1 (en) 2017-12-01 2018-11-29 Glucocorticoid receptor agonist and immunoconjugates thereof

Publications (1)

Publication Number Publication Date
LT3658192T true LT3658192T (lt) 2021-07-12

Family

ID=65010803

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP18833113.6T LT3658192T (lt) 2017-12-01 2018-11-29 Gliukokortikoidų receptorių agonistas ir jo imunokonjugatai

Country Status (35)

Country Link
US (2) US10772970B2 (lt)
EP (2) EP3884962A1 (lt)
JP (2) JP6813712B2 (lt)
KR (1) KR20200095477A (lt)
CN (1) CN111417410B (lt)
AU (1) AU2018374634A1 (lt)
BR (1) BR112020010694A2 (lt)
CA (1) CA3082356A1 (lt)
CL (2) CL2020001452A1 (lt)
CO (1) CO2020006446A2 (lt)
CR (1) CR20200239A (lt)
CY (1) CY1124230T1 (lt)
DK (1) DK3658192T3 (lt)
DO (1) DOP2020000116A (lt)
EC (1) ECSP20029001A (lt)
ES (1) ES2877659T3 (lt)
HR (1) HRP20210917T1 (lt)
HU (1) HUE054428T2 (lt)
IL (1) IL274651B (lt)
LT (1) LT3658192T (lt)
MA (1) MA49796A (lt)
MX (1) MX2020005583A (lt)
PE (1) PE20201286A1 (lt)
PH (1) PH12020550779A1 (lt)
PL (1) PL3658192T3 (lt)
PT (1) PT3658192T (lt)
RS (1) RS61994B1 (lt)
RU (1) RU2020117698A (lt)
SG (1) SG11202004867WA (lt)
SI (1) SI3658192T1 (lt)
TW (1) TWI803542B (lt)
UA (1) UA126595C2 (lt)
UY (1) UY37991A (lt)
WO (1) WO2019106609A1 (lt)
ZA (1) ZA202003325B (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49796A (fr) * 2017-12-01 2020-06-03 Abbvie Inc Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci
CN116096413A (zh) * 2020-04-22 2023-05-09 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
WO2022166779A1 (zh) * 2021-02-04 2022-08-11 上海森辉医药有限公司 糖皮质激素受体激动剂的药物偶联物及其在医药上的应用
AR125079A1 (es) 2021-03-23 2023-06-07 Lilly Co Eli Agonistas de receptores de glucocorticoides sustituidos con carboxi
TW202304462A (zh) * 2021-03-23 2023-02-01 美商美國禮來大藥廠 糖皮質素受體激動劑
TW202304464A (zh) 2021-03-23 2023-02-01 美商美國禮來大藥廠 新穎糖皮質素受體激動劑
EP4365183A1 (en) * 2021-06-24 2024-05-08 Jiangsu Simcere Pharmaceutical Co., Ltd. Steroid compound, and pharmaceutical composition thereof and use thereof
EP4393937A1 (en) * 2021-08-26 2024-07-03 Duality Biologics (Suzhou) Co., Ltd. Steroid compound and conjugate thereof
TW202327620A (zh) * 2021-09-14 2023-07-16 大陸商映恩生物製藥（蘇州）有限公司 一種抗炎症的化合物及其用途
TW202340252A (zh) 2022-01-29 2023-10-16 大陸商上海盛迪醫藥有限公司 糖皮質激素的藥物偶聯物
US20240218011A1 (en) 2022-07-21 2024-07-04 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024064779A1 (en) * 2022-09-22 2024-03-28 Eli Lilly And Company Glucocorticoid receptor agonists
TW202430226A (zh) * 2022-12-28 2024-08-01 大陸商上海盛迪醫藥有限公司 抗cd40抗體藥物偶聯物、其製備方法及其醫藥用途
WO2024149093A1 (zh) * 2023-01-10 2024-07-18 四川科伦博泰生物医药股份有限公司 糖皮质激素受体激动剂及其偶联物
WO2024153162A1 (en) * 2023-01-18 2024-07-25 Shanghai Micurx Pharmaceutical Co., Ltd. Peptide-drug conjugates for targeted therapy of renal diseases
WO2025026216A1 (zh) * 2023-07-28 2025-02-06 江苏恒瑞医药股份有限公司 一种含有糖皮质激素的抗体药物偶联物的药物组合物

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
GB933868A (en) 1958-12-08 1963-08-14 American Cyanamid Co Process for fluorinating steroids
IT1057859B (it) 1972-04-28 1982-03-30 Sigma Tao Ind Farmaceutiche Sp Perivato del triamoinolone
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5010176A (en) 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994022899A1 (de) 1993-04-02 1994-10-13 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue prednisolonderivate
WO1994025478A1 (en) 1993-04-29 1994-11-10 Instytut Farmaceutyczny 16α,17α-ACETAL GLUCOCORTICOSTEROIDAL DERIVATIVES
DK0749438T3 (da) 1994-03-09 2001-04-02 Byk Gulden Lomberg Chem Fab Hidtil ukendte silylforbindelser og deres anvendelse
JP2749778B2 (ja) 1994-09-05 1998-05-13 日清食品株式会社 トリアムシノロン誘導体
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5792758A (en) 1995-12-08 1998-08-11 G. D. Searle & Co. Steroid nitrite ester derivatives useful as anti-inflammatory drugs
BRPI9715219B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Vetor recombinante de expressão, e célula hospedeira procariótica.
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
DE19635498A1 (de) 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
WO2000049993A2 (en) 1999-02-24 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
DE10055820C1 (de) 2000-11-10 2002-07-25 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung eines Glucocorticoids
KR100809510B1 (ko) 2000-11-10 2008-03-04 니코메드 게엠베하 트랜스케탈화 반응에 의한 16,17-[(시클로헥실메틸렌)비스(옥시)]-11,21-디히드록시-프레그나-1,4-디엔-3,20-디온또는 이의 21-이소부티라트의 제조방법
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP2305314B1 (en) 2001-10-10 2015-12-23 ratiopharm GmbH Remodelling and glycoconjugation of antibodies
CA2466592A1 (en) 2001-11-12 2003-05-22 Koen Hellendoorn Modified anti-tnf alpha antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
AU2003265576A1 (en) 2002-08-23 2004-03-11 The Mclean Hospital Corporation Corticosteroid conjugates and uses thereof
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004037197A2 (en) 2002-10-24 2004-05-06 Goldstein Jay A Antifungal formulations
US20040156869A1 (en) 2002-12-13 2004-08-12 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues
CA2512174A1 (en) 2003-01-30 2004-08-12 Christian B. Allan Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof
MY143936A (en) 2003-03-27 2011-07-29 Nycomed Gmbh Process for preparing crystalline ciclesonide with defined particle size
WO2005044759A2 (en) 2003-08-14 2005-05-19 Sun Pharmaceutical Industries Limited Acetalization process for preparation of steroid compounds
AU2004271744B2 (en) 2003-09-16 2010-07-29 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases
WO2005028495A1 (en) 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
JP4836798B2 (ja) 2003-10-21 2011-12-14 アイジーエフ オンコロジー エルエルシー 癌を治療するための化合物および方法
JP4616839B2 (ja) 2003-11-13 2011-01-19 エフ．ホフマン−ラ ロシュ アーゲー ヒドロキシアルキル置換ピリド−７−ピリミジン−７−オン類
US7378418B2 (en) 2003-12-19 2008-05-27 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
WO2005063777A1 (en) 2003-12-23 2005-07-14 Corus Pharma Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
EP3238708A1 (en) 2003-12-31 2017-11-01 CyDex Pharmaceuticals, Inc. Inhalant formulation containing cyclodextrin and corticosteroid
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
DK2471813T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
CN104710532B (zh) 2004-09-03 2019-01-18 健泰科生物技术公司 人源化的抗-β7拮抗剂及其应用
JP2008512428A (ja) 2004-09-10 2008-04-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング シクレソニドとＳｙｋインヒビターとの組合せ物並びにその使用方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2587589A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
WO2006097458A1 (en) 2005-03-15 2006-09-21 Nycomed Gmbh Novel combination
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
WO2006135479A2 (en) 2005-05-10 2006-12-21 Angiotech International Ag Anti-scarring agents, therapeutic compositions, and use thereof
CN101227912A (zh) 2005-06-14 2008-07-23 基利得科学公司 用于治疗肺炎和支气管收缩的作为类固醇和β-激动剂的协同前药的取代苯基磷酸酯
US20070160617A1 (en) 2005-06-20 2007-07-12 Psma Development Company, Llc PSMA antibody-drug conjugates
WO2007054974A2 (en) 2005-09-28 2007-05-18 Arch Pharmalab Limited A green chemistry process for the preparation of pregnadiene esters
WO2007117685A2 (en) 2006-04-07 2007-10-18 Nektar Therapeutics Al, Corporation Conjugates of an anti-tnf-alpha antibody
WO2008015696A2 (en) 2006-05-23 2008-02-07 Cadila Healthcare Limited Process for preparing ciclesonide
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
EP2392584A1 (en) 2006-09-19 2011-12-07 Cipla Limited Crystalline Ciclesonide Methanol Solvate Form C
WO2008052350A1 (en) 2006-11-03 2008-05-08 Qlt Inc. Photodynamic therapy for the treatment of hidradenitis suppurativa
NO331891B1 (no) 2007-03-20 2012-04-30 Clavis Pharma Asa Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
JP2010531898A (ja) 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
CA2706180C (en) * 2007-11-30 2012-10-23 Pfizer Limited Novel glucocorticoid receptor agonists
JP2011507879A (ja) 2007-12-21 2011-03-10 シェーリング コーポレイション グルココルチコイド受容体アゴニストとしてのｃ−２１チオエーテル
US8524697B2 (en) 2007-12-21 2013-09-03 Merck Sharp & Dohme Corp. C20-C21 substituted glucocorticoid receptor agonists
US20100303828A1 (en) 2008-01-31 2010-12-02 INSERM Institut National de la Sante et de la Recherche Medicale) Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
JP2011513303A (ja) 2008-02-27 2011-04-28 アストラゼネカ・アクチエボラーグ １６アルファ，１７アルファ−アセタールグルココルチコステロイド誘導体およびその使用
WO2009112557A2 (en) 2008-03-13 2009-09-17 Farmabios S.P.A. Process for the preparation of pregnane derivatives
WO2009152171A1 (en) 2008-06-10 2009-12-17 Gilead Sciences, Inc. Corticosteroid linked beta-agonist compounds for use in therapy
AU2009271401A1 (en) 2008-06-16 2010-01-21 Immunogen Inc. Novel synergistic effects
MX2010014569A (es) 2008-06-24 2011-03-29 Irm Llc Compuestos y metodos para modular los receptores acoplados con proteina-g.
US20100120733A1 (en) 2008-11-07 2010-05-13 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
CN102300879A (zh) 2008-12-04 2011-12-28 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
EP2786762B1 (en) 2008-12-19 2019-01-30 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CA2754589C (en) 2009-03-09 2013-07-16 Mikasa Seiyaku Co., Ltd. Steroid compound
WO2010126953A1 (en) 2009-04-29 2010-11-04 Gilead Sciences, Inc. Corticosteroid linked beta-agonist compounds for use in therapy
WO2010132743A1 (en) 2009-05-15 2010-11-18 Gilead Sciences, Inc. Corticosteroid beta-agonist compounds for use in therapy
SG175738A1 (en) 2009-05-29 2011-12-29 Pfizer Ltd Novel glucocorticoid receptor agonists
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
MX2012006406A (es) 2009-12-04 2012-07-25 Genentech Inc Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
CA2782398C (en) 2009-12-09 2017-09-26 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
CN102167741B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗TNF-α单克隆抗体、其制备方法及用途
AU2011237679B2 (en) 2010-04-07 2014-11-06 Abbvie Inc. TNF-alpha binding proteins
MX346731B (es) 2010-04-23 2017-03-30 Genentech Inc * Producción de proteínas heteromultiméricas.
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use
DK2575884T3 (en) 2010-06-03 2018-09-03 Abbvie Biotechnology Ltd APPLICATIONS AND COMPOSITIONS TO TREAT HIDRADENITIS SUPPURATIVA (HS)
TW201204831A (en) 2010-06-24 2012-02-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2812262A1 (en) 2010-09-22 2012-03-29 Map Pharmaceuticals, Inc. Aerosol composition for administering drugs
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
WO2012082947A1 (en) 2010-12-16 2012-06-21 Irm Llc Compounds and compositions as tgr5 agonists
US9848048B2 (en) 2010-12-29 2017-12-19 Nokia Solutions And Networks Oy Method and apparatus for transmitting an identity
CN106039306A (zh) 2011-03-30 2016-10-26 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
TW201326207A (zh) 2011-10-24 2013-07-01 Abbvie Inc 抗ｔｎｆ免疫結合物
EP2771361A1 (en) 2011-10-24 2014-09-03 AbbVie Inc. Bispecific immunobinders directed against tnf and il-17
US20130115269A1 (en) 2011-11-04 2013-05-09 Henry John Smith Anti-tumor necrosis factor alpha (TNF-a) antibody used as a targeting agent to treat arthritis and other diseases
EP2791171A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9109005B2 (en) 2012-02-23 2015-08-18 Boehringer Ingelheim International Gmbh Method for manufacturing of ciclesonide
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2647627A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
CN103421075B (zh) 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
US20150158943A1 (en) 2012-06-01 2015-06-11 Momenta Pharmaceuticals, Inc. Methods related to adalimumab
CN104854133B (zh) 2012-10-12 2018-10-30 新加坡科技研究局 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
EP2922818B1 (en) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
MX364652B (es) 2012-12-21 2019-05-03 Boehringer Ingelheim Vetmedica Gmbh Formulacion farmaceutica que comprende ciclesonida.
EP2970458A1 (en) 2013-03-15 2016-01-20 AbbVie Inc. Improved tnf binding proteins
WO2015047510A1 (en) 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3122757B1 (en) 2014-02-28 2023-09-06 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
WO2015153401A1 (en) * 2014-04-04 2015-10-08 Merck Sharp & Dohme Corp Phosphate based linkers for intracellular delivery of drug conjugates
EP3160499A4 (en) 2014-06-30 2018-03-14 Immunomedics, Inc. Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
EP3193829B1 (en) 2014-09-19 2021-12-08 Oxular Limited Ophthalmic drug compositions
EP3250211B1 (en) 2015-01-30 2021-12-22 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
JP2016190798A (ja) 2015-03-31 2016-11-10 三笠製薬株式会社 アレルギー性鼻炎治療用局所点鼻薬
AU2015242210A1 (en) 2015-06-15 2017-12-07 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers for conjugation
WO2015151079A2 (en) 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Auristatin analogues and their conjugates with cell-binding molecules
WO2015155753A2 (en) 2015-08-10 2015-10-15 Suzhou M-Conj Biotech Co., Ltd Novel linkers and their uses in specific conjugation of drugs to a biological molecule
JP2017066075A (ja) 2015-09-30 2017-04-06 三笠製薬株式会社 リウマチ治療薬
MX2018014927A (es) 2016-06-02 2019-04-09 Abbvie Inc Agonista del receptor de glucocorticoides e inmumoconjugados del mismo.
JP6767796B2 (ja) 2016-07-08 2020-10-14 株式会社日立情報通信エンジニアリング 通話管理システム及びその音声認識制御方法
AU2017359043B2 (en) 2016-11-08 2022-06-16 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
MA49796A (fr) * 2017-12-01 2020-06-03 Abbvie Inc Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci

Also Published As

Publication number Publication date
UA126595C2 (uk) 2022-11-02
CN111417410A (zh) 2020-07-14
HUE054428T2 (hu) 2021-09-28
CL2021001075A1 (es) 2021-10-15
US20190167804A1 (en) 2019-06-06
ECSP20029001A (es) 2020-06-30
RS61994B1 (sr) 2021-07-30
PE20201286A1 (es) 2020-11-24
PH12020550779A1 (en) 2021-04-19
CO2020006446A2 (es) 2020-06-09
SG11202004867WA (en) 2020-06-29
JP2021054845A (ja) 2021-04-08
CR20200239A (es) 2020-09-21
EP3884962A1 (en) 2021-09-29
CL2020001452A1 (es) 2020-09-11
SI3658192T1 (sl) 2021-08-31
DOP2020000116A (es) 2020-08-31
IL274651B (en) 2021-04-29
RU2020117698A (ru) 2022-01-04
IL274651A (en) 2020-06-30
US10772970B2 (en) 2020-09-15
DK3658192T3 (da) 2021-06-21
WO2019106609A1 (en) 2019-06-06
CA3082356A1 (en) 2019-06-06
ES2877659T3 (es) 2021-11-17
JP2021501124A (ja) 2021-01-14
AU2018374634A1 (en) 2020-05-28
HRP20210917T1 (hr) 2021-09-03
CN111417410B (zh) 2023-06-23
EP3658192B1 (en) 2021-04-28
MX2020005583A (es) 2020-11-25
RU2020117698A3 (lt) 2022-01-04
EP3658192A1 (en) 2020-06-03
CY1124230T1 (el) 2022-05-27
TW201924723A (zh) 2019-07-01
PL3658192T3 (pl) 2021-10-18
PT3658192T (pt) 2021-06-25
KR20200095477A (ko) 2020-08-10
UY37991A (es) 2019-06-28
ZA202003325B (en) 2021-07-28
US20210015938A1 (en) 2021-01-21
JP6813712B2 (ja) 2021-01-13
BR112020010694A2 (pt) 2020-11-10
TWI803542B (zh) 2023-06-01
MA49796A (fr) 2020-06-03

Similar Documents

Publication Publication Date Title
LT3658192T (lt) Gliukokortikoidų receptorių agonistas ir jo imunokonjugatai
ZA201808623B (en) Glucocorticoid receptor agonist and immunoconjugates thereof
EP3609888A4 (en) FARNESOID X RECEPTOR AGONISTS AND THEIR USES
EP3596053A4 (en) FARNESOID X RECEPTOR AGONISTS AND THEIR USES
EP3615567A4 (en) Chimeric antibody/t-cell receptor constructs and uses thereof
IL258405A (en) Antibody/t-cell receptor chimeric constructs and uses thereof
LT3368534T (lt) Valbenazino ditozilatas ir jo polimorfai
LT3558390T (lt) Amanitino ir antikūnų konjugatai
EP3675479A4 (en) IMAGING DEVICE AND APPARATUS
LT3409259T (lt) Daugiakamerinis lankstus maišelis ir jo panaudojimo būdai
HK1255312A1 (zh) 抗原受體及其用途
LT3394065T (lt) Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
EP3573104A4 (en) LIGHT RECEPTION ELEMENT, IMAGING ELEMENT AND IMAGING DEVICE
DK3169703T3 (da) Kimær antigenreceptor og anvendelse deraf
EP3644602A4 (en) IMAGING ELEMENT, LAMINATE IMAGING ELEMENT AND SEMICONDUCTOR IMAGING DEVICE
EP3703321A4 (en) CONFIGURATION PROCESS AND APPARATUS
HUE064654T2 (hu) Állítható hüvelyes eszköz
EP3594221A4 (en) GPR84 RECEIVER ANTAGONIST AND ITS USE
EP3712667A4 (en) IMAGING DEVICE
EP3734965A4 (en) IMAGING DEVICE
EP3669583A4 (en) CELL PROHIBITION PROCESS AND APPARATUS
EP3888498A4 (en) SEAT ROTATION DEVICE
EP3787372A4 (en) INFRARED RADIATION DEVICE
EP3635047A4 (en) AMORPHIC COPOLYMERS OF PROPYLENE-ETHYLENE
EP3744738A4 (en) CHEMERICAL ANTIGENIC RECEPTOR AND RELATED APPLICATION